Fairness opinions › By year

Healthcare fairness opinions, 2023

10 public-company healthcare transactions announced in 2023 with a fairness opinion in the SEC filing.

2023 valuation benchmarks

EV / LTM EBITDA
16.1x
median · n=10
EV / LTM revenue
1.53x / 2.61x / 6.44x
Q1 / median / Q3 · n=10
DCF discount rate (midpoint)
10.0% / 11.0% / 13.0%
Q1 / median / Q3 · n=10

Transactions announced in 2023. Multiples are enterprise value over the last-twelve-months figure disclosed in the filing; the discount rate is the midpoint of the range the banker used in its DCF.

AnnouncedTargetAcquirerSegment EVEV/EBITDAEV/RevDCF rateFairness opinion
2023-10-17 Olink Holding AB Thermo Fisher Scientific Diagnostics / Life Sciences $3.0B591.4x14.79x10.5%–11.5% J.P. Morgan, Goldman Sachs
2023-09-05 NextGen Healthcare Thoma Bravo Digital / HealthTech $1.8B16.1x2.76x8.9%–10.6% Morgan Stanley
2023-08-28 Abcam Danaher Diagnostics / Life Sciences $5.7B29.1x11.05x8.9%–10.8% Morgan Stanley, Lazard
2023-08-07 Tabula Rasa HealthCare Nautic Partners / ExactCare Pharmacy Digital / HealthTech $570M27.1x1.58x13.0%–15.5% Goldman Sachs
2023-06-26 Amedisys UnitedHealth Group Home-Based Services $3.6B15.2x1.59x8.3%–10.5% Guggenheim Securities
2023-05-10 Syneos Health Elliott Investment Management / Patient Square Capital / Veritas Capital Pharmaceutical Services $7.1B9.7x1.38x12.0%–14.0% Centerview Partners
2023-02-09 NuVasive Globus Medical Medical Devices and Supplies $3.1B10.6x2.46x7.5%–9.5%
2023-02-08 Cardiovascular Systems Abbott Medical Devices and Supplies $850M3.32x10.5%–12.5% J.P. Morgan
2023-02-08 Oak Street Health CVS Health Physician Groups $11B4.90x11.3%–13.5% Centerview Partners
2023-01-31 Chembio Diagnostics Biosynex SA Diagnostics / Life Sciences $17.2M0.55x16.0%–20.0% Craig-Hallum

← 2022 · 2024 →